Hype vs. reality: What pharma’s hottest R&D bets have actually proved

Hype vs. reality: What pharma’s hottest R&D bets have actually proved is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Sy Mukherjee · 2026-10-15

New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.

Source: PharmaVoice